| Entry |
|
|---|
| Name |
Bivalirudin trifluoroacetate (USAN);
Angiomax (TN) |
|---|
| Product |
|
|---|
| Generic |
BIVALIRUDIN (Accord Healthcare), BIVALIRUDIN (Athenex Pharmaceutical Division), BIVALIRUDIN (Avenacy), BIVALIRUDIN (Civica), BIVALIRUDIN (Dr. Reddy's Laboratories Limited), BIVALIRUDIN (Eugia US LLC), BIVALIRUDIN (Fresenius Kabi USA), BIVALIRUDIN (Fresenius Kabi USA), BIVALIRUDIN (Hainan Shuangcheng Pharmaceuticals), BIVALIRUDIN (Hospira), BIVALIRUDIN (Meitheal Pharmaceuticals), BIVALIRUDIN (Meitheal Pharmaceuticals), BIVALIRUDIN (Mylan Institutional LLC), BIVALIRUDIN (Pharma Packaging Solutions), BIVALIRUDIN (Sandoz), BIVALIRUDIN (Sandoz), BIVALIRUDIN (Slate Run Pharmaceuticals) |
|---|
| Formula |
C98H138N24O33. (C2HF3O2)2
|
|---|
| Exact mass |
2406.9715
|
|---|
| Mol weight |
2408.332
|
|---|
| Class |
Blood modifier agent
DG01950 Antithrombotic agent
DG01511 Thrombin inhibitor
|
|---|
| Remark |
| Product (DG02963): | D11280<US> |
|
|---|
| Efficacy |
Anticoagulant, Thrombin inhibitor |
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04610 | Complement and coagulation cascades |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01511 Thrombin inhibitor
DG02963 Bivalirudin
D11280 Bivalirudin trifluoroacetate
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Serine peptidases
F2
D11280 Bivalirudin trifluoroacetate (USAN) <US>
Drug groups [BR:br08330]
Blood modifier agent
DG01950 Antithrombotic agent
DG01511 Thrombin inhibitor
DG02963 Bivalirudin
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
